Method and material for treating immune diseases
CA 2451885 A1 · Owner: Sasek, Vodek · Inventors: Sasek, Vodek; Chang, Yan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An immune response in an organism is controlled by administering to said organism a therapeutically effective amount of a compound which binds to a galectin. In specific instances the compound is selected to bind to galectin-1 or galectin-3. Some therapeutic materials comprise natural or synthetic polymers having galactose or arabinose terminated side chains pendent therefrom. A group of preferred therapeutic compounds comprise modified pectins or other materials having a substantially demethoxylated rhamnogalacturan backbone having rhamnose residues interrupting the backbone. One therapeutic material includes a first functional portion which binds to the carbohydrate binding …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 21, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 21, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 21, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.